Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials

Cyrus Desouza, Bertrand Cariou, Satish Garg, Nanna Lausvig, Andrea Navarria & Vivian Fonseca
Context: Variations in the prevalence and aetiology of type 2 diabetes (T2D) across race and ethnicity may affect treatment responses. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog approved for once–weekly, subcutaneous (s.c.) treatment of T2D. Objective: To compare semaglutide efficacy and safety in race and ethnicity subgroups across the SUSTAIN trials. Design: Post hoc analysis of data from phase 3 randomized SUSTAIN 1–5 and 7 (pooled) and SUSTAIN 6 trials. Participants: 3,074 subjects (SUSTAIN 1–5...

Registration Year

  • 2019
    1

Resource Types

  • Dataset
    1

Affiliations

  • L’Institut du Cancer Courlancy Reims
    1
  • University of Nebraska Medical Center
    1
  • University of Colorado Denver
    1
  • Fundación Universitaria de Ciencias de la Salud
    1